Although the CellSearchTM platform (Veridex LLC, Huntingdon Valley, PA, USA) uses antibodies against the adhesion molecule (EpCAM)-coated with magnetic beads, cytokeratin (CK8, CK18 and CK19) antibodies and negative staining for the CD45 (CD45-) antibody to isolate and exclusively quantify the E+ CTCs, it remains the main method used in GC studies and is the only technique approved for the enumeration and isolation of CTCs by the Food and Drug Administration (FDA) for clinical use in the prognosis of breast, colorectal and prostate cancer [39]. Here, PTPRC is linked to Familial prostate cancer.